Influence of heat shock protein 70 and metallothionein induction by zinc-bis-(DL-hydrogenaspartate) on the release of inflammatory mediators in a porcine model of recurrent endotoxemia

Biochemical Pharmacology

Volumn 52, Issue 8, 1996, Pages 1201-1210

  Klosterhalfen, B ^a   Tons C ^c   Hauptmann, S ^c   Tietze, L ^c   Offner, F A ^b   Kupper W ^c   Kirkpatrick, C J ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c NONE

Author keywords

cytokines; heat shock protein 70; lipopolysaccharide; metallothionein; sepsis prevention; zinc

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HEAT SHOCK PROTEIN 70; INTERLEUKIN 1BETA; INTERLEUKIN 6; METALLOTHIONEIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC BIS(HYDROGENASPARTATE); ZINC DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENDOTOXEMIA; GENE EXPRESSION; HEART OUTPUT; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; LUNG ARTERY PRESSURE; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN INDUCTION; RECURRENT DISEASE; SEPTIC SHOCK; SWINE;

EID: 0030601799     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00469-8     Document Type: Article

References (64)

1. 1. Traber DL, Schlag G, Redl H, Strohmair W and Traber LD, Pulmonary microvascular changes during hyperdynamic sepsis in an ovine model. Circ Shock 22: 185-193, 1987.
2. 2. Hinshaw LB and Beller BK, Septic shock. 2. Physiological aspects. In: Shock: The Reversible Stage of Dying (Ed. Hardaway RM), pp. 178-185. PSG Publishing Company, Littleton, MA, 1988.
3. 3. Oettinger W and Beger HG, How specific is eicosanoid release in the surgical sepsis syndrome? Current state of clinical evidence. Theor Surg 3: 171-180, 1989.
4. 4. Oettinger W, Walte GO, Jensen UM, Beyer A and Peskar A, Endogenous prostaglandin F2 in the hyperdynamic state of severe sepsis in man. Br J Surg 70: 237-239, 1983.
5. 5. Lefer AM, Significance of lipid mediators in shock states. Circ Shock 27: 3-12, 1989.
6. 6. Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN and Shen TY, Platelet-activating factor (PAF) involvement in endotoxin-induced hypotension. Studies with PAF receptor antagonist kadsurenone. Biochem Biophys Res Commun 127: 799-808, 1985.
7. 7. Terashita Z, Imura Y, Nishikawa K and Sumida S, Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol 109(2): 257-261, 1985.
8. 8. Handley DA, Van-Valen RG, Melden MK, Flury S, Lee ML and Saunders RN, Inhibition and reversal of endotoxin-, aggregated IgG- and PAF-induced hypotension in the rat by SRI 63-072, a PAF receptor antagonist. Immunopharmacology 12(1): 11-16, 1986.
9. 9. Chang SW, Feddersen CO, Henson PM and Voelkel NF, Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79(5): 1498-1509, 1987.
10. 10. Dobrowsky RT, Voyksner RD and Olson NC, Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia. Am J Physiol 260: H1455-H1465, 1991.
11. 11. Flohè S, Heinrich PC, Schneider J, Wendel A and Flohè L, Time course of IL-6 and TNF alpha release during endotoxin-induced endotoxin tolerance in rats. Biochem Pharmacol 41: 1607-1614, 1991.
12. 12. Dinarello CA, Biology of interleukin 1. FASEB J 2: 108-115, 1988.
13. 13. Haak CE, De Groot ER, Felt-Bersma JR, Nuijens JH, Strack van Schijndel RJM, Erenberg-Belmer AJ, Thijs LG and Aarden LA, Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704-1710, 1989.
14. 14 Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Standford GG, Van Der Meer JWM, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF and Dinarello CA, Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161: 79-84, 1990.
15. 15. Flohè L and Giertz H, Endotoxins, arachidonic acid and superoxid formation. In: Perspectives on Bacterial Pathogenesis and Host Defense (Ed. Urbascheck B), pp. 123-131. University of Chicago Press, Chicago, 1988.
16. 16. Fritz H, Jochum M, Daswald KH, Dittmer H, Kortmann H, Neumann S and Lang H, Granulocyte proteinases as mediators of unspecific proteolysis in inflammation: a review in proteinases in inflammation and tumor invasion. In: Proteinaxes in Inflammation and Tumor Invasion (Ed. Tschesche H), pp. 1-23. Walter de Gruyter, Berlin, 1986.
17. 17. West RL, Elovitz MJ and Hardaway RM, Blood coagulation factors activity in experimental endotoxemia. Ann Surg 163: 567-572, 1966.
18. 18. Snedegard G, Lui L and Hugli TE, Endotoxin induced shock in the rat. A role of C5a. Am J Pathol 135: 489-497, 1989.
19. 19. Wenzel RP, Pinsky MR, Ulevitch RJ and Young L, Current understanding of sepsis. Clin Infect Dis 22: 407-413, 1996.
20. 20. Ziegler EJ, McCutchan JA, Fierer J, Glanser MP, Sadoff JC, Douglas H and Braude AI, Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307: 1225-1230, 1982.
21. 21. Ziegler EJ, Fisher CJ Jr, Sprung CI, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF and Smith CR, Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324: 429-436, 1991.
22. 22. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J and Russell JA, A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266: 1097-1102, 1991.
23. 23. Warren HS, Danner RL and Munford RS, Antiendotoxin monoclonal antibodies. N Engl J Med 326: 1153-1157, 1992.
24. 24. McCloskey RV, Straube RC, Sanders C, Smith SM and Smith CR, Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121: 1-5, 1994.
25. 25. Fisher CJ Jr, Dhainaut J-FA, Opal SM, Fribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalane MA, Knaus WA and Sadoff JC, Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1RA Sepsis Syndrome Study Group. JAMA 271: 1836-1843, 1994.
26. 26. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE and Wherry JC, Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: a randomized, controlled, multicenter clinical trial. TNF-α MAb Sepsis Study Group. JAMA 273: 934-941, 1995.
27. 27. Lindquist S and Craig EA, The heat-shock proteins. Annu Rev Genet 22: 631-677, 1988.
28. 28. Nover L, Heat Shock Response of Eukaryottc Cells. Springer-Verlag, Berlin, 1984.
29. 29. Riabowol KT, Mizzen LA and Welch WJ, Heat shock is lethal to fibroblasts microinjected with antibodies against HSP70. Science 242: 433-436, 1988.
30. 30. Schlesinger MJ, Heat shock proteins. J Biol Chem 265: 12111-12114, 1990.
31. 31. Ribeiro SP, Villar J, Downey G, Edleson JD and Slutsky AS, Sodium arsenite induces heat shock protein-72 kilodalton expression in the lungs and protects rats against sepsis. Crit Care Med 22: 922-929, 1994.
32. 32. Villar J, Ribeiro SP, Mullen BM, Kuliszewski M, Post M and Slutsky AS, Induction of heat shock response reduces mortality rate and organ damage in a sepsis-induced acute lung injury model. Crit Care Med 22: 914-921, 1994.
33. 33. Ryan AJ, Flanagan SW, Moseley PL and Gisolfi CV, Acute heat stress protects rats against endotoxin shock. J Appl Physiol 73(4): 1517-1522, 1992.
34. 34. Singh KP, Zaidi SI, Raisuddin S, Saxena AK, Murthy RC and Ray PK, Effect of zinc on immune functions and host resistance against infection and tumor challenge. Immunopharmacol Immunotoxicol 14(4): 813-840, 1992.
35. 35. Ribeiro SP, Villar J, DeHoyos A and Slutsky AS, Heat stress decreases tumor necrosis factor release in LPS-stimulated alveolar macrophages. Am Rev Respir Dis 147: A229, 1993.
36. 36. Hall TJ, Role of HSP70 in cytokine production. Experientia 50(11-12): 1048-1053, 1994.
37. 37. Driessen C, Hirv K, Kirchner H and Rink L, Zinc regulates cytokine induction by superantigens and lipopolysaccharide. Immunology 84(2): 272-277, 1995.
38. 38. Driessen C, Hirv K, Rink L and Kirchner H, Induction of cytokines by zinc ions in human peripheral blood mononuclear cells and separated monocytes. Lymphokine Cytokine Res 13(1): 15-20, 1994.
39. 39. Klosterhalfen B, Hörstmann-Jungemann K, Vogel P, Flohe S, Offner F, Kirkpatrick CJ, Heinrich PC, Time course of various inflammatory mediators during recurrent endotoxemia. Biochem Pharmacol 43: 2103-2109, 1992.
40. 40. Shen R, Hornback NB, Shidnia H, Wu B and Broxmeyer HE, Whole body hyperthermia: a potent radioprotector in vivo. Int J Radiat Oncol Biol Phys 10: 525-530, 1991.
41. 41. Fraker DL, Strovroff MC, Merino MJ and Norton JA, Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med 168: 95-105, 1988.
42. 42. Van Der Meer JW, Barza M, Wolf SM, and Dinarello CA, A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 85: 1620-1623, 1988.
43. 43. Flohè S, Heinrich PC, Schneider J, Wendel A and Flohè L, Time course of IL-6 and TNF alpha release during endotoxin-induced endotoxin tolerance in rats. Biochem Pharmacol 41: 1607-1614, 1991.
44. 44. Sanchez-Cantu L, Rode HN, and Cristou NV, Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg 124: 1432-1436, 1989.
45. 45. Mathison JC, Wolfson E and ULevitch RJ, Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81: 1925-1937, 1988.
46. 46. Zuckermann SH, Evans GF, Snyder YM and Roeder WD, Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J Immunol 143: 1223-1227, 1989.
47. 47. Virca GD, Kim SY, Glaser KB and Ulevitch RJ, lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells. J Biol Chem 264: 21951-21956, 1989.
48. 48. Waage A, Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol 45: 348-355, 1987.
49. 49. Cross AS, Sadoff JC, Kelly N, Bernton E and Gemski P, Pretreatment with recombinant murine tumor necrosis factor α/cachectin and murine interleukin 1α protects mice from lethal bacterial infection. J Exp Med 169: 2021-2027, 1989.
50. 50. Jäattella M, Saksela K and Saksela E, Heat shock protects WEHI-164 target cells from the cytolysis by tumor necrosis factor α and β. Eur J Immunol 19: 1413-1417, 1989.
51. 51. Larrick JW and Wright SC, Cytotoxic mechanisms of tumor necrosis factor-α. FASEB J 4: 3215-3223, 1990.
52. 52. Schmidt JA and Abdulla E, Down-regulation of IL-1β biosynthesis by inducers of the heat-shock response. J Immunol 141: 2027-2034, 1988.
53. 53. Velasco S, Tarlow M, Olsen K, Shay JW, McCracken GH and Nisen PD, Temperature-dependent modulation of lipopolysaccharide-induced interleukin-1β and tumor necrosis factor-α expression in cultured human astroglial cells by dexamethasone and indomethacin. J Clin Invest 87: 1674-1680, 1991.
54. 54. Currie RW and White FP, Characterization of the synthesis and accumulation of a 71-kilodalton protein induced in rat tissues after hyperthermia. Can J Biochem Cell Biol 61: 438-446, 1983.
55. 55. Godsoe A, Kimura R, Herndon D, Flynn J, Schlag G, Traber L and Traber DL, Cardiopulmonary changes with continuous endotoxin administration in sheep. Circ Shock 25: 61-74, 1988.
56. 56. Traber DL, Redl H, Schlag G, Herndon DN, Kimura R, Prien T and Traber LD, Cardiopulmonary responses to continuous administration of endotoxin. Am J Physiol 254: H833-H839, 1988.
57. 57. Traber DL, Flynn JT, Herndon DN, Redl H, Schlag G and Traber LD, Comparison of the cardiopulmonary responses to single bolus and continuous infusion of endotoxin in an ovine model. Circ Shock 27: 123-138, 1989.
58. 58. D'Orio V, Wahlen C, Rodriguez LM, Fossion A, Juchmes J, Halleux J and Marcelle R, A comparison of escherichia coli endotoxin single bolus injection with low-dose endotoxin infusion on pulmonary and systemic vascular changes. Circ Shock 21: 207-216, 1987.
59. 59. Fish RE and Spitzer JA, Continuous infusion of endotoxin from an osmotic pump in the conscious, unstrained rat: a unique model of chronic endotoxemia. Circ Shock 12: 135-149, 1984.
60. 60. Fish RE, Lang CH and Spitzer JA, Regional blood flow during continuous low-dose endotoxin infusion. Circ Shock 18: 267-275, 1986.
61. 61. Chandra RK, Excessive intake of zinc impairs immune responses. JAMA 252: 1443-1446, 1984.
62. 62. Tengrup I and Samuelson H, Changes in serum zinc during and after surgical procedures. Acta Chit Scand 143: 195-199, 1977.
63. 63. Hallbook T and Hedelin H, Zinc metabolism and surgical traumas. Br J Surg 64: 271-273, 1977.
64. 64. Prasad AS, Fitzgerald JT, Hess JW, Kaplan J, Pelen F and Dardenne M, Zinc deficiency in elderly patients. Nutrition 9: 218-224, 1993.